Oxford, UK - 1 May 2020:Circassia Group plc ('Circassia' or 'the Company'; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, announces that it has today granted 6,806,199 nominal and nil-cost cost options ('Options') over new ordinary shares in the Company ('Ordinary Shares') to the Executive Directors under the 2019 Performance Share Plan.
Name
Price per Ordinary Share
Number of shares subject to award
Michael Roller
Nil
4,000,000
Ian Johnson
Nil
1,677,233
Jonathan Emms
0.08p
1,128,966
The Options will vest on the third anniversary of the date of grant and are exercisable until the tenth anniversary of the date of grant. Vesting is subject to either the price of an Ordinary Share reaching 62.4p for at least 30 consecutive dealing days or a liquidity event occurring above this level.
Contacts
Circassia
Ian Johnson, Executive Chairman
Michael Roller, Chief Financial Officer
c/o Peel Hunt
Peel Hunt (Nominated Adviser and Joint Broker)
James Steel / Oliver Jackson
Tel: +44 (0) 20 7418 8900
finnCap (Joint Broker)
Geoff Nash / Alice Lane
Tel: +44 (0) 20 7220 0500
Numis Securities (Joint Broker)
James Black / Freddie Barnfield
Tel: +44 (0) 20 7260 1000
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1.
Details of the person discharging managerial responsibilities / person closely associated
a.
Name
Ian Johnson
Michael Roller
Jonathan Emms
2.
Reason for the notification
a.
Position/status
Executive Chairman
Chief Financial Officer
Chief Operating Officer
b.
Initial notification
/Amendment
Initial notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
Circassia Group plc
b.
LEI
2138006YAT138TOGA556
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the
Financial instrument, type of instrument
Identification code
Options over Ordinary shares of 0.08p each.
GB00BJVD3B28 ISIN for the Ordinary shares
b.
Nature of the transaction
Award of share options granted under the 2019 Performance Share Plan over Ordinary Shares in Circassia
c.
Price(s) and volume(s)
Price(s)
Volume(s)
nil
4,000,000
nil
1,677,233
0.08p
1,128,966
d.
Aggregated information
· Aggregated volume
· Price
n/a
e.
Date of the transaction
1 May 2020
f.
Place of the transaction
Outside a trading venue
Attachments
Original document
Permalink
Disclaimer
Circassia Pharmaceuticals plc published this content on 01 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 May 2020 10:18:08 UTC
NIOX Group plc is a United Kingdom-based diagnostics and management company that is focused on asthma. The Company's product NIOX uses patented technology to measure fractional exhaled nitric oxide (FeNO). Its NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The Company offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The Company offers products and services in around 50 countries.
NIOX GROUP PLC 
